Venus Concept Announces First Quarter 2025 Financial Results
- Operating expenses decreased 6% year-over-year through cost containment initiatives
- Successfully completed two equity offerings raising $2.67 million in gross proceeds
- Restructured $11.0 million of convertible notes through exchange for preferred stock
- Revenue declined 22% year-over-year to $13.6 million
- Net loss increased to $12.4 million from $9.8 million last year
- Adjusted EBITDA loss widened to $8.3 million from $5.1 million
- Gross margin decreased to 64.2% from 66.6% year-over-year
- Low cash position of $3.2 million with significant debt of $35.5 million
Insights
Venus Concept faces deteriorating financial performance with declining revenue, widening losses, and concerning cash position despite fundraising efforts.
Venus Concept's Q1 2025 results reveal a 22% year-over-year revenue decline to
Looking at revenue composition, the company experienced weakness across all segments: systems revenue through both direct sales (
The company's gross margin contracted to
Most concerning is the precarious cash position. As of March 31, Venus had just
The company appears to be in financial distress, evidenced by sequential small capital raises, debt restructuring, and management's reluctance to provide 2025 guidance while citing "active dialogue with existing lenders and investors" and "ongoing evaluation of strategic alternatives." The
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025.
Summary of Financial Results & Recent Progress:
- Total revenue for the first quarter of
$13.6 million , down22% year-over-year, reflecting continued difficult market conditions.- First quarter operating expenses declined
6% year-over-year - First quarter GAAP net loss of
$12.4 million , compared to$9.8 million last year - First quarter Adjusted EBITDA loss of
$8.3 million , compared to$5.1 million last year
- First quarter operating expenses declined
- On April 1, 2025, the Company exchanged
$11.0 million of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 379,311 shares of its Series Y preferred stock. - On April 10, 2025, the Company announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,573 shares of common stock at a purchase price of
$3.50 per share. The gross proceeds to the Company from the offering were approximately$1.1 million , before deducting placement agent fees and other offering expenses payable by the Company. - On April 14, 2025, the Company announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of
$4.06 per share. The gross proceeds to the Company from the offering were approximately$1.57 million , before deducting placement agent fees and other offering expenses payable by the Company.
Management Commentary:
“Our team delivered solid execution despite the continued challenging environment,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “Our first quarter revenue results came in modestly softer than expectations due to the timing of new system adoption expected in late-March, that closed in early April. We are navigating the challenging operating environment and are targeting revenue growth on a sequential basis in the second quarter. Our focus remains on managing our cash burn through disciplined cost management and making targeted investments to support our long-term growth. We enhanced our balance sheet condition subsequent to quarter-end with a new bridge loan amendment from Madryn and two equity capital transactions which together represent further validation - from existing and new investors - of the potential value creation opportunity Venus offers.”
First Quarter 2025 Financial Results:
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (dollars in thousands) | ||||||||
| Revenues by region: | ||||||||
| United States | $ | 8,407 | $ | 10,073 | ||||
| International | 5,236 | 7,406 | ||||||
| Total revenue | $ | 13,643 | $ | 17,479 | ||||
| Three Months Ended March 31, | ||||||||||||||||||||||
| 2025 | 2024 | Change | ||||||||||||||||||||
| (in thousands, except percentages) | $ | % of Total | $ | % of Total | $ | % | ||||||||||||||||
| Revenues by product: | ||||||||||||||||||||||
| Venus Prime / Subscription—Systems | $ | 2,649 | 19.4 | $ | 3,531 | 20.2 | $ | (882 | ) | (25.0 | ) | |||||||||||
| Products—Systems | 7,903 | 57.9 | 10,535 | 60.3 | (2,362 | ) | (25.0 | ) | ||||||||||||||
| Products—Other | 2,420 | 17.8 | 2,557 | 14.6 | (137 | ) | (5.4 | ) | ||||||||||||||
| Services | 671 | 4.9 | 856 | 4.9 | (185 | ) | (21.6 | ) | ||||||||||||||
| Total | $ | 13,643 | 100.0 | $ | 17,479 | 100.0 | $ | (3,836 | ) | (21.9 | ) | |||||||||||
Total revenue for the first quarter of 2025 decreased
Gross profit for the first quarter of 2025 decreased
Operating expenses for the first quarter of 2025 decreased
Operating loss for the first quarter of 2025 was
Net loss attributable to stockholders for the first quarter of 2025 was
As of March 31, 2025, the Company had cash and cash equivalents of
Fiscal Year 2025 Financial Outlook:
Given the Company’s active dialogue with existing lenders and investors, ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value, and assessment of potential trade disruptions, the Company is not providing full year 2025 financial guidance at this time.
Conference Call Details:
Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at: 877-660-6853 (201-612-7415 for international callers); access code 13753054. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors, including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management and Aperture Venture Partners.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, but are not limited to, statements about our financial performance and metrics; the growth in demand for our systems and other products; the efficacy of the restructuring plan; the identification and efficacy of strategic alternatives to maximize shareholder value; the reduction in our cash burn; and the continued implementation of turnaround plans, including debt restructurings and financings. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part II Item 1A—“Risk Factors” in our Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
Investor Relations Contact:
ICR Healthcare on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
| Venus Concept Inc. | ||||||||
| Condensed Consolidated Balance Sheets (In thousands of U.S. dollars, except share and per share data) | ||||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 3,199 | $ | 4,271 | ||||
| Accounts receivable, net of allowance of | 16,782 | 18,721 | ||||||
| Inventories | 17,633 | 17,561 | ||||||
| Prepaid expenses | 743 | 828 | ||||||
| Advances to suppliers | 6,036 | 6,027 | ||||||
| Other current assets | 1,212 | 1,104 | ||||||
| Total current assets | 45,605 | 48,512 | ||||||
| LONG-TERM ASSETS: | ||||||||
| Long-term receivables, net of allowance of | 8,213 | 8,534 | ||||||
| Deferred tax assets | 1,119 | 1,459 | ||||||
| Severance pay funds | 477 | 488 | ||||||
| Property and equipment, net | 851 | 936 | ||||||
| Operating right-of-use assets, net | 3,079 | 3,282 | ||||||
| Intangible assets | 4,116 | 4,973 | ||||||
| Total long-term assets | 17,855 | 19,672 | ||||||
| TOTAL ASSETS | $ | 63,460 | $ | 68,184 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Trade payables | $ | 7,372 | $ | 6,484 | ||||
| Accrued expenses and other current liabilities | 10,513 | 11,433 | ||||||
| Note payable | 13,910 | 8,271 | ||||||
| Unearned interest income | 828 | 907 | ||||||
| Warranty accrual | 806 | 917 | ||||||
| Deferred revenues | 880 | 953 | ||||||
| Operating lease liabilities | 1,300 | 1,322 | ||||||
| Total current liabilities | 35,609 | 30,287 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Long-term debt | 21,565 | 31,437 | ||||||
| Accrued severance pay | 517 | 528 | ||||||
| Unearned interest income | 341 | 364 | ||||||
| Warranty accrual | 172 | 222 | ||||||
| Operating lease liabilities | 1,803 | 1,997 | ||||||
| Other long-term liabilities | 725 | 511 | ||||||
| Total long-term liabilities | 25,123 | 35,059 | ||||||
| TOTAL LIABILITIES | 60,732 | 65,346 | ||||||
| Commitments and Contingencies (Note 9) | ||||||||
| STOCKHOLDERS’ EQUITY (Note 14): | ||||||||
| Common Stock, | 30 | 30 | ||||||
| Additional paid-in capital | 323,494 | 311,238 | ||||||
| Accumulated deficit | (321,262 | ) | (308,899 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 2,262 | 2,369 | ||||||
| Non-controlling interests | 466 | 469 | ||||||
| 2,728 | 2,838 | |||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 63,460 | $ | 68,184 | ||||
| Venus Concept Inc. Condensed Consolidated Statements of Operations (In thousands of U.S. dollars, except per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | ||||||||
| Leases | $ | 2,649 | $ | 3,593 | ||||
| Products and services | 10,994 | 13,886 | ||||||
| 13,643 | 17,479 | |||||||
| Cost of goods sold: | ||||||||
| Leases | 844 | 1,477 | ||||||
| Products and services | 4,044 | 4,355 | ||||||
| 4,888 | 5,832 | |||||||
| Gross profit | 8,755 | 11,647 | ||||||
| Operating expenses: | ||||||||
| Selling and marketing | 6,992 | 7,374 | ||||||
| General and administrative | 9,735 | 10,248 | ||||||
| Research and development | 1,556 | 1,785 | ||||||
| Total operating expenses | 18,283 | 19,407 | ||||||
| Loss from operations | (9,528 | ) | (7,760 | ) | ||||
| Other expenses: | ||||||||
| Foreign exchange (gain) loss | (119 | ) | 324 | |||||
| Finance expenses | 1,570 | 1,668 | ||||||
| Loss on debt extinguishment | 1,049 | — | ||||||
| Loss before income taxes | (12,028 | ) | (9,752 | ) | ||||
| Income tax expense | 338 | 37 | ||||||
| Net loss | $ | (12,366 | ) | $ | (9,789 | ) | ||
| Net loss attributable to stockholders of the Company | $ | (12,363 | ) | $ | (9,794 | ) | ||
| Net (loss) income attributable to non-controlling interest | $ | (3 | ) | $ | 5 | |||
| Net loss per share: | ||||||||
| Basic | $ | (17.44 | ) | $ | (16.92 | ) | ||
| Diluted | $ | (17.44 | ) | $ | (16.92 | ) | ||
| Weighted-average number of shares used in per share calculation: | ||||||||
| Basic | 709 | 579 | ||||||
| Diluted | 709 | 579 | ||||||
| Venus Concept Inc. Condensed Consolidated Statements of Cash Flows (in thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (12,366 | ) | $ | (9,789 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 950 | 975 | ||||||
| Stock-based compensation | 207 | 339 | ||||||
| Provision for expected credit losses | 1,172 | 171 | ||||||
| Provision for inventory obsolescence | 569 | 372 | ||||||
| Finance expenses and accretion | 1,634 | 481 | ||||||
| Deferred tax expense (recovery) | 341 | (120 | ) | |||||
| Loss on extinguishment of debt | 1,049 | — | ||||||
| Loss on disposal of property and equipment | 27 | 5 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable short-term and long-term | 1,226 | 3,226 | ||||||
| Inventories | (641 | ) | 1,722 | |||||
| Prepaid expenses | 85 | 264 | ||||||
| Advances to suppliers | (9 | ) | 678 | |||||
| Other current assets | (107 | ) | 417 | |||||
| Operating right-of-use assets, net | 203 | 437 | ||||||
| Other long-term assets | (139 | ) | (1 | ) | ||||
| Trade payables | 914 | (1,251 | ) | |||||
| Accrued expenses and other current liabilities | (1,104 | ) | (263 | ) | ||||
| Current operating lease liabilities | (22 | ) | (172 | ) | ||||
| Severance pay funds | 11 | 144 | ||||||
| Unearned interest income | (102 | ) | 29 | |||||
| Long-term operating lease liabilities | (194 | ) | (316 | ) | ||||
| Other long-term liabilities | (14 | ) | (226 | ) | ||||
| Net cash used in operating activities | (6,310 | ) | (2,878 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | (35 | ) | (25 | ) | ||||
| Net cash used in investing activities | (35 | ) | (25 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of common stock | — | 10 | ||||||
| 2024 Registered Direct Offering shares and warrants, net of costs of | — | 977 | ||||||
| 2024 Convertible Notes issued to EW, net of costs of | — | 1,607 | ||||||
| Proceeds from Short-term Bridge Financing by Madryn, net of costs of | 5,273 | — | ||||||
| Net cash provided by financing activities | 5,273 | 2,594 | ||||||
| NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (1,072 | ) | (309 | ) | ||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period | 4,271 | 5,396 | ||||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period | $ | 3,199 | $ | 5,087 | ||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for income taxes | $ | 1 | $ | 27 | ||||
| Cash paid for interest | $ | — | $ | 1,187 | ||||
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net income (loss) before foreign exchange (gain) loss, financial expenses, income tax expense (benefit), depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.
The following is a reconciliation of net loss to Adjusted EBITDA for the periods presented:
| Venus Concept Inc. Reconciliation of Net loss to Non-GAAP Adjusted EBITDA | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Reconciliation of net loss to adjusted EBITDA | (in thousands) | |||||||
| Net loss | $ | (12,366 | ) | $ | (9,789 | ) | ||
| Foreign exchange (gain) loss | (119 | ) | 324 | |||||
| Loss on debt extinguishment | 1,049 | — | ||||||
| Finance expenses | 1,570 | 1,668 | ||||||
| Income tax expense | 338 | 37 | ||||||
| Depreciation and amortization | 950 | 975 | ||||||
| Stock-based compensation expense | 207 | 339 | ||||||
| CEWS(1) | — | 418 | ||||||
| Other adjustments(2) | 27 | 910 | ||||||
| Adjusted EBITDA | $ | (8,344 | ) | $ | (5,118 | ) | ||
(1) In April 2022, the Canada Revenue Agency (“CRA”) initiated an audit of the Canada Emergency Wage Subsidy Claim (“CEWS”) that the Company filed between 2020-2021. The CRA has currently assessed a denial of CEWS claims made by the Company in 2020 and requesting repayment of
(2) For the three months ended March 31, 2025 and March 31, 2024 the other adjustments are represented by restructuring activities designed to improve the Company's operations and cost structure.
FAQ
What were Venus Concept's (VERO) key financial results for Q1 2025?
How much cash and debt does Venus Concept (VERO) have as of March 2025?
What strategic actions did Venus Concept (VERO) take to improve its financial position in Q1 2025?
Why isn't Venus Concept (VERO) providing guidance for 2025?
How did Venus Concept's (VERO) regional performance change in Q1 2025?
